Another such study among individuals with inflammatory bowel syndrome (144,018 individuals with IBD and 720,090 matched controls) reported a 78% reduction in the incidence of PD among the population when anti-TNF therapy was previously utilized to treat symptoms related to the inflammatory bowel syndrome compared to those who were never exposed to anti-TNF therapy (Peter et al., 2018). The gene discussed is TNF; the disease is inflammatory bowel disease.